04:56 PM EST, 02/26/2025 (MT Newswires) -- Corcept Therapeutics ( CORT ) reported Q4 net income late Wednesday of $0.26 per diluted share, down from $0.28 a year earlier.
Revenue for the quarter ended Dec. 31 was $181.9 million, up from $135.4 million a year earlier.
Analysts surveyed by FactSet expected $198.7 million.
The company said it expects 2025 revenue of $900 million to $950 million. Analysts expected $841.6 million.